Courtney Lawrence: It’s Critical That as Blood Donor Eligibility Criteria Evolves, We Ensure the U.S. Blood Supply for Patients Remains Safe!
Courtney Lawrence, Divisional Chief Medical Officer at the American Red Cross, shared on LinkedIn:
”It’s critical that as blood donor eligibility criteria evolves, we sensure the U.S. blood supply for patients remains safe!
With supporting data from the experiences of other countries and ongoing studies of specific donor subpopulations, the FDA reduced the deferral period for blood donors with specific higher risk behaviors from 12 months to 3 months in 2020.
(In 2023, another huge stride was made in moving to Individualized Donor Assessment, replacing blanket deferrals based on gender and sexual orientation with evidence-based individual assessments of risks).
‘Despite reducing donor deferral periods for many infectious risk behaviors, HIV and HBV prevalence were stable, while HCV prevalence declined over 8 years.
Either slight or significant declines occurred from the pre-3M to 3M period for all agents.
Thus, changes in policy did not adversely impact the current safety of the blood supply with respect to the major infectious disease agents.’
Congratulations to the science teams from American Red Cross’s Transfusion Safety and Surveillance, Vitalant, OneBlood, New York Blood Center and the FDA on their collaborative publication in AABB Transfusion!”

Stay updated on the emerging with Hemostasis Today.
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
-
Sep 3, 2026, 01:03SHOT Urges Safe Component Matching While NHSBT Appeals for Black Donors
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden